{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:41:50Z","timestamp":1792428110730,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05195-3","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:06:21Z","timestamp":1784631981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of immunosuppressive therapy in low-risk and intermediate- risk idiopathic membranous nephropathy patients : a 2-year follow-up study"],"prefix":"10.1186","volume":"27","author":[{"given":"Yan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"2","key":"5195_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26(2):414\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfq665.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"5195_CR2","doi-asserted-by":"publisher","first-page":"2555688","DOI":"10.1080\/0886022x.2025.2555688","volume":"47","author":"X Li","year":"2025","unstructured":"Li X, Song L, Wang L, et al. Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study. Ren Fail. 2025;47(1):2555688. https:\/\/doi.org\/10.1080\/0886022x.2025.2555688.","journal-title":"Ren Fail"},{"issue":"4","key":"5195_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/asn.2009080861","volume":"21","author":"N Polanco","year":"2010","unstructured":"Polanco N, Guti\u00e9rrez E, Covars\u00ed A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697\u2013704. https:\/\/doi.org\/10.1681\/asn.2009080861.","journal-title":"J Am Soc Nephrol"},{"key":"5195_CR4","doi-asserted-by":"publisher","unstructured":"KDIGO, Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s). s1-s276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"5","key":"5195_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","volume":"89","author":"T Lee","year":"2016","unstructured":"Lee T, Derebail VK, Kshirsagar AV, et al. Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89(5):1111\u20138. https:\/\/doi.org\/10.1016\/j.kint.2015.12.041.","journal-title":"Kidney Int"},{"key":"5195_CR6","doi-asserted-by":"publisher","first-page":"917532","DOI":"10.3389\/fphar.2022.917532","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Li X, Huang T, et al. Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis. Front Pharmacol. 2022;13:917532. https:\/\/doi.org\/10.3389\/fphar.2022.917532.","journal-title":"Front Pharmacol"},{"issue":"2","key":"5195_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","volume":"16","author":"TT Qiu","year":"2017","unstructured":"Qiu TT, Zhang C, Zhao HW, et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials. Autoimmun Rev. 2017;16(2):136\u201345. https:\/\/doi.org\/10.1016\/j.autrev.2016.12.005.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"5195_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3109\/08860221003728754","volume":"32","author":"G Kosmadakis","year":"2010","unstructured":"Kosmadakis G, Filiopoulos V, Smirloglou D, et al. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Ren Fail. 2010;32(5):566\u201371. https:\/\/doi.org\/10.3109\/08860221003728754.","journal-title":"Ren Fail"},{"issue":"1","key":"5195_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1681\/asn.2013020185","volume":"25","author":"JA van den Brand","year":"2014","unstructured":"van den Brand JA, van Dijk PR, Hofstra JM, et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014;25(1):150\u20138. https:\/\/doi.org\/10.1681\/asn.2013020185.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"5195_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F \u200cScolari","year":"2021","unstructured":"\u200cScolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972\u201382. https:\/\/doi.org\/10.1681\/ASN.2020071091.","journal-title":"J Am Soc Nephrol"},{"issue":"29","key":"5195_CR11","doi-asserted-by":"publisher","first-page":"e2404151","DOI":"10.1002\/advs.202404151","volume":"11","author":"A Cai","year":"2024","unstructured":"Cai A, Meng Y, Zhou H, et al. Podocyte Pathogenic Bone Morphogenetic Protein-2 Pathway and Immune Cell Behaviors in Primary Membranous Nephropathy. Adv Sci (Weinh). 2024;11(29):e2404151. https:\/\/doi.org\/10.1002\/advs.202404151.","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"5195_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jfma.2017.01.004","volume":"116","author":"CK Chan","year":"2017","unstructured":"Chan CK, Lai TS, Chen PM, et al. Early initiation of immunosuppressive treatment in membranous nephropathy patients. J Formos Med Assoc. 2017;116(4):266\u201375. https:\/\/doi.org\/10.1016\/j.jfma.2017.01.004.","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"5195_CR13","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","volume":"96","author":"AE van de Logt","year":"2019","unstructured":"van de Logt AE, Fresquet M, Wetzels JF, et al. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292\u2013302. https:\/\/doi.org\/10.1016\/j.kint.2019.07.014.","journal-title":"Kidney Int"},{"issue":"6","key":"5195_CR14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/asn.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899\u2013904. https:\/\/doi.org\/10.1681\/asn.2007020166.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5195_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427.","journal-title":"N Engl J Med"},{"issue":"1","key":"5195_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2169\/internalmedicine.43.30","volume":"43","author":"S Fujimoto","year":"2004","unstructured":"Fujimoto S, Hara S, Sato Y, et al. Nephrotic syndrome caused by membranous nephropathy: response to a short course of cyclophosphamide alternating with prednisolone. Intern Med. 2004;43(1):30\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.43.30.","journal-title":"Intern Med"},{"issue":"1","key":"5195_CR17","doi-asserted-by":"publisher","first-page":"2205951","DOI":"10.1080\/0886022X.2023.2205951","volume":"45","author":"M Sun","year":"2023","unstructured":"Sun M, Li P, Dong J, Li Z, Li C, Zhang S, Chen B. Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage. Ren Fail. 2023;45(1):2205951. https:\/\/doi.org\/10.1080\/0886022X.2023.2205951.","journal-title":"Ren Fail"},{"key":"5195_CR18","doi-asserted-by":"publisher","first-page":"789713","DOI":"10.3389\/fimmu.2022.789713","volume":"13","author":"F Scolari","year":"2022","unstructured":"Scolari F, Alberici F, Mescia F, Delbarba E, Trujillo H, Praga M, Ponticelli C. Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia. Front Immunol. 2022;13:789713. https:\/\/doi.org\/10.3389\/fimmu.2022.789713.","journal-title":"Front Immunol"},{"issue":"5","key":"5195_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.23876\/j.krcp.22.255","volume":"43","author":"JY Choi","year":"2024","unstructured":"Choi JY, Chin HJ, Lee H, et al. Effect of immunosuppressive agents on clinical outcomes in idiopathic membranous nephropathy. Kidney Res Clin Pract. 2024;43(5):635\u201347. https:\/\/doi.org\/10.23876\/j.krcp.22.255.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"5195_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12882-022-02914-4","volume":"23","author":"B Wang","year":"2022","unstructured":"Wang B, Zhu Z, Huang F, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients. BMC Nephrol. 2022;23(1):306. https:\/\/doi.org\/10.1186\/s12882-022-02914-4.","journal-title":"BMC Nephrol"},{"issue":"5","key":"5195_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/03007995.2023.2192608","volume":"39","author":"M Sun","year":"2023","unstructured":"Sun M, Huang J, Dong J, et al. Comparative analysis of the efficacy of different treatments for idiopathic membranous nephropathy: a retrospectively real-world study. Curr Med Res Opin. 2023;39(5):761\u20139. https:\/\/doi.org\/10.1080\/03007995.2023.2192608.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"5195_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/ki.1997.127","volume":"51","author":"DC Cattran","year":"1997","unstructured":"Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997;51(3):901\u20137. https:\/\/doi.org\/10.1038\/ki.1997.127.","journal-title":"Kidney Int"},{"issue":"10","key":"5195_CR23","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/cjn.0000000000000237","volume":"18","author":"SJ Barbour","year":"2023","unstructured":"Barbour SJ, Fervenza FC, Induruwage D, et al. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy. Clin J Am Soc Nephrol. 2023;18(10):1283\u201393. https:\/\/doi.org\/10.2215\/cjn.0000000000000237.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"5195_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1159\/000527368","volume":"47","author":"R Paulo","year":"2022","unstructured":"Paulo R, Jorge LB, Yu L, et al. Diagnosis and Course of Membranous Nephropathy in Adults: Comparison by Age Group. Kidney Blood Press Res. 2022;47(12):693\u2013701. https:\/\/doi.org\/10.1159\/000527368.","journal-title":"Kidney Blood Press Res"},{"key":"5195_CR25","doi-asserted-by":"publisher","unstructured":"Song EJ, Jeong KH, Yang YA et al. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy. Kidney Res Clin Pract. 2018;37(3):248\u2013256. https:\/\/doi.org\/10.23876\/j.krcp.2018.37.","DOI":"10.23876\/j.krcp.2018.37"},{"issue":"9","key":"5195_CR26","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.3390\/jcm14092880","volume":"14","author":"K Krakowska-Jura","year":"2025","unstructured":"Krakowska-Jura K, Kler AN, Wajerowska W, et al. Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy. J Clin Med. 2025;14(9):2880. https:\/\/doi.org\/10.3390\/jcm14092880.","journal-title":"J Clin Med"},{"issue":"1","key":"5195_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/0886022x.2021.1879853","volume":"43","author":"P Zou","year":"2021","unstructured":"Zou P, Li H, Cai J, et al. Statins can benefit patients with primary membranous nephropathy on venous thromboembolism. Ren Fail. 2021;43(1):302\u20136. https:\/\/doi.org\/10.1080\/0886022x.2021.1879853.","journal-title":"Ren Fail"},{"issue":"12","key":"5195_CR28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/ndt\/gfaf165","volume":"40","author":"GQ Shi","year":"2025","unstructured":"Shi GQ, Yu R, Wu Y, et al. Obinutuzumab for PLA2R-associated membranous nephropathy. Nephrol Dial Transpl. 2025;40(12):2401\u20133. https:\/\/doi.org\/10.1093\/ndt\/gfaf165.","journal-title":"Nephrol Dial Transpl"},{"key":"5195_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/itt.S512451","volume":"14","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Zou Y, Ke B, et al. How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study. Immunotargets Ther. 2025;14:515\u201322. https:\/\/doi.org\/10.2147\/itt.S512451.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"5195_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ndt\/gfad156","volume":"39","author":"Y Duan","year":"2023","unstructured":"Duan Y, Bai Y, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrol Dial Transpl. 2023;39(1):95\u2013102. https:\/\/doi.org\/10.1093\/ndt\/gfad156.","journal-title":"Nephrol Dial Transpl"},{"key":"5195_CR31","unstructured":"Alok A, Yadav A. Membranous Nephropathy. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Anju Yadav declares no relevant financial relationships with ineligible companies. StatPearls Publishing Copyright \u00a9; 2025."},{"issue":"1","key":"5195_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000510153","volume":"7","author":"R Eren Sadioglu","year":"2021","unstructured":"Eren Sadioglu R, Eyupoglu S, Erdogmus S, et al. Infectious Complications in Patients with Primary Glomerulonephritis over 10 Years: A Single-Center Experience in Turkey. Kidney Dis (Basel). 2021;7(1):57\u201366. https:\/\/doi.org\/10.1159\/000510153.","journal-title":"Kidney Dis (Basel)"},{"key":"5195_CR33","doi-asserted-by":"publisher","first-page":"111718","DOI":"10.1016\/j.intimp.2024.111718","volume":"130","author":"P Yan","year":"2024","unstructured":"Yan P, Fang X, Ke B, et al. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study. Int Immunopharmacol. 2024;130:111718. https:\/\/doi.org\/10.1016\/j.intimp.2024.111718.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"5195_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12882-024-03784-8","volume":"25","author":"AS Artan","year":"2024","unstructured":"Artan AS, Mirio\u011flu \u015e, Hocao\u011flu RH, et al. Observational study of immunosuppressive treatment patterns and outcomes in primary membranous nephropathy: a multicenter retrospective analysis. BMC Nephrol. 2024;25(1):327. https:\/\/doi.org\/10.1186\/s12882-024-03784-8.","journal-title":"BMC Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05195-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05195-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:23Z","timestamp":1792425743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05195-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5195"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05195-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committee of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) (Approval No.: 2025-RE-436).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants in accordance with the guiding principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Consent form","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there are no financial and non-financial relationships and activities, and conflicts of interest to disclose.","order":3,"name":"Ethics","label":"Disclosure statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"617"}}